These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
477 related items for PubMed ID: 12597346
1. Management of clinical stage I nonseminomatous germ-cell testis tumors. Flechon A, Droz JP. Expert Rev Anticancer Ther; 2003 Feb; 3(1):21-30. PubMed ID: 12597346 [Abstract] [Full Text] [Related]
2. The management of stage I nonseminomatous testicular germ cell tumors. Pectasides D, Farmakis D, Pectasides M. Oncology; 2006 Feb; 71(3-4):151-8. PubMed ID: 17646698 [Abstract] [Full Text] [Related]
3. [Management of localized germ-cell tumours of the testis]. Loriot Y, Fizazi K. Rev Prat; 2007 Feb 28; 57(4):379-84. PubMed ID: 17455739 [Abstract] [Full Text] [Related]
4. Current management of stage I testicular non-seminomatous germ cell tumours. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. Crit Rev Oncol Hematol; 2009 May 28; 70(2):114-23. PubMed ID: 18805019 [Abstract] [Full Text] [Related]
9. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Sogani PC. Urol Clin North Am; 1991 Aug 28; 18(3):561-73. PubMed ID: 1652171 [Abstract] [Full Text] [Related]
10. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle. Yoon GH, Stein JP, Skinner DG. Expert Rev Anticancer Ther; 2005 Feb 28; 5(1):75-85. PubMed ID: 15757440 [Abstract] [Full Text] [Related]
11. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only. Ondrus D, Ondrusova M, Hornak M, Matoska J. Neoplasma; 2007 Feb 28; 54(5):437-42. PubMed ID: 17688374 [Abstract] [Full Text] [Related]
12. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors. Kondagunta GV, Motzer RJ. Urol Clin North Am; 2007 May 28; 34(2):179-85; abstract ix. PubMed ID: 17484923 [Abstract] [Full Text] [Related]
15. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Nicolai N, Miceli R, Necchi A, Biasoni D, Catanzaro M, Milani A, Piva L, Pizzocaro G, Stagni S, Torelli T, Salvioni R. Eur Urol; 2010 Dec 28; 58(6):912-8. PubMed ID: 20817343 [Abstract] [Full Text] [Related]
16. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. J Urol; 2005 Dec 28; 174(6):2209-13, discussion 2213. PubMed ID: 16280765 [Abstract] [Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, Sheinfeld J. Cancer; 2008 Feb 15; 112(4):800-5. PubMed ID: 18172902 [Abstract] [Full Text] [Related]
18. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. J Urol; 2007 Mar 15; 177(3):937-42; discussion 942-3. PubMed ID: 17296380 [Abstract] [Full Text] [Related]
19. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer. Williams SB, Steele GS, Richie JP. J Urol; 2009 Dec 15; 182(6):2716-20. PubMed ID: 19836777 [Abstract] [Full Text] [Related]